Latest Clinical Validation News

Nexsen has locked in over $1.5 million in non-dilutive funding through a national research partnership, accelerating manufacturing scale-up and platform optimisation for its rapid diagnostics technology.

CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.

TALi Digital is transforming its established educational programs into an AI-driven platform, leveraging a validated cognitive technology and a national footprint in over 500 schools to tap a largely under-penetrated market.

BCAL Diagnostics has developed BREASTEST Monitor, a blood test showing promising accuracy in detecting local breast cancer recurrence in women over 50, aiming to simplify post-treatment monitoring.

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

Echo IQ has partnered with Mayo Clinic to assess its AI platform's ability to predict heart failure risk in patients undergoing cancer therapy, targeting the growing cardio-oncology sector.

TruScreen has secured clinical validation from the world’s largest cervical screening study in China, setting the stage for rapid market expansion across Asia, Africa, and Europe.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.

Micro-X has captured the first human head images using its innovative carbon nanotube cone beam CT technology, marking a major technical milestone as it launches a multi-centre pilot study aimed at stroke diagnosis.

Imagion Biosystems has secured FDA clearance to proceed with its Phase 1b/2 trial of the MagSense® HER2 Imaging Agent, targeting improved detection of HER2+ breast cancer. Patient recruitment is expected to start in Q3 2026, marking a crucial step toward commercialisation.

Optiscan and Mayo Clinic have completed all key engineering milestones in their two-year partnership to develop a digital endomicroscopic imaging system for robotic surgery, extending their agreement to support further clinical and commercial planning.